Infectious Disease and Microbiology - Trypanosomiasis: American (Chagas Disease) and African (Sleeping Sickness)

Basics

Description

Trypanosomiasis refers to a group of zoonotic protozoal infections caused by Trypanosoma species and transmitted primarily by blood-feeding insect vectors.

Two major human diseases are recognized:

• American trypanosomiasis (Chagas disease) — caused by Trypanosoma cruzi
• Human African trypanosomiasis (sleeping sickness) — caused by Trypanosoma brucei gambiense or T. brucei rhodesiense

Although both are caused by trypanosomes, their vectors, geographic distributions, clinical manifestations, diagnostic approaches, and treatments are substantially different.

Chagas disease is particularly important because chronic infection can eventually cause severe cardiomyopathy, arrhythmias, megaesophagus, and megacolon.

African trypanosomiasis initially produces a systemic hemolymphatic illness and later invades the central nervous system, producing the characteristic sleep and neurologic disturbances responsible for the term sleeping sickness.

⸻

Etiology

American trypanosomiasis

Chagas disease is caused by:

Trypanosoma cruzi

The principal vector is the triatomine bug, also called the:

• Kissing bug
• Reduviid bug

Unlike many vector-borne infections, the parasite is not primarily transmitted through the insect’s saliva during the bite.

Instead, the infected bug defecates near the bite site, and parasites in the feces enter through damaged skin or mucous membranes.

⸻

African trypanosomiasis

Human African trypanosomiasis is transmitted by the tsetse fly (Glossina species).

Two major organisms cause disease.

Trypanosoma brucei gambiense

Causes West and Central African trypanosomiasis.

It typically produces a relatively slowly progressive, chronic illness, developing over months to years.

Trypanosoma brucei rhodesiense

Causes East and Southern African trypanosomiasis.

It generally produces a more acute and rapidly progressive disease, often developing over weeks to months.

⸻

Epidemiology

Chagas disease

T. cruzi infection is primarily associated with:

• Mexico
• Central America
• South America

Historically, the greatest burden has occurred in rural areas of Latin America where triatomine insects can colonize poorly constructed housing.

Migration has resulted in infected individuals living throughout North America, Europe, and other regions outside traditional endemic areas.

Locally acquired vector-borne infection in the United States is possible but uncommon.

⸻

African trypanosomiasis

Human African trypanosomiasis occurs in sub-Saharan Africa, corresponding to the geographic distribution of the tsetse fly.

T. b. gambiense historically accounts for most cases and occurs primarily in West and Central Africa.

T. b. rhodesiense occurs mainly in East and Southern Africa.

The geographic distribution is therefore an important clue when distinguishing the two forms.

⸻

Risk factors

Chagas disease

Important risk factors include:

• Residence in endemic areas
• Poor-quality rural housing
• Mud or adobe houses that permit triatomine infestation
• Exposure to infected triatomine bugs
• Consumption of food or beverages contaminated with T. cruzi
• Receiving infected blood products
• Receiving an infected organ transplant
• Maternal infection during pregnancy

Immunosuppression can cause reactivation of latent Chagas disease, particularly in patients with:

• HIV infection
• Organ transplantation
• Other major forms of immunosuppression

⸻

African trypanosomiasis

Risk is associated primarily with exposure to tsetse flies in endemic regions of sub-Saharan Africa.

Exposure may occur through:

• Residence in endemic rural regions
• Agricultural activities
• Hunting
• Fishing
• Travel to affected game parks or rural areas

⸻

Transmission of Chagas disease

T. cruzi can be transmitted by several mechanisms.

Vector-borne transmission

This is the classic route.

The triatomine bug feeds on human blood and subsequently deposits infected feces near the bite.

Scratching or rubbing allows parasites to enter through:

• Broken skin
• The bite wound
• Conjunctiva
• Other mucosal surfaces

Congenital transmission

An infected pregnant woman can transmit T. cruzi across the placenta to the fetus.

Blood transfusion

Transmission through infected blood products can occur, although screening programs have substantially reduced this risk in countries where blood donations are routinely tested.

Organ transplantation

An infected donor organ can transmit the parasite to a seronegative recipient.

Oral transmission

Outbreaks have occurred after consumption of food or beverages contaminated with infected triatomine material.

⸻

Pathophysiology of Chagas disease

After entering the human body, T. cruzi trypomastigotes invade host cells and transform into intracellular amastigotes.

The organisms multiply intracellularly and subsequently differentiate back into trypomastigotes, which enter the bloodstream and infect additional tissues.

Over time, chronic inflammation, tissue destruction, fibrosis, and autonomic neuronal injury can produce characteristic chronic complications.

The organs most importantly affected are:

• Heart
• Esophagus
• Colon
• Nervous system

⸻

Clinical presentation of Chagas disease

Chagas disease can be divided into:

1. Acute infection
2. Chronic indeterminate infection
3. Chronic determinate disease

⸻

Acute Chagas disease

Acute disease generally develops after initial infection and is often mild, particularly in children.

Many patients have few or no symptoms.

Possible manifestations include:

• Fever
• Malaise
• Fatigue
• Lymphadenopathy
• Hepatomegaly
• Splenomegaly
• Local inflammatory lesions

Most acute manifestations resolve spontaneously over several weeks.

⸻

Chagoma

A chagoma is an inflammatory lesion that develops at the site where T. cruzi enters through the skin.

It typically appears as:

• Indurated papule
• Local erythema
• Swelling
• Regional lymphadenopathy

⸻

Romaña sign

Romaña sign is a classic manifestation of acute Chagas disease.

It occurs when the parasite enters through the conjunctiva.

The patient develops:

• Unilateral painless periorbital or eyelid edema
• Conjunctival inflammation
• Regional lymphadenopathy

This finding in a patient from an endemic region strongly suggests acute Chagas disease.

⸻

Severe acute Chagas disease

Although uncommon, acute infection can occasionally produce:

• Myocarditis
• Pericardial involvement
• Meningoencephalitis

Severe disease occurs more frequently in young children and immunocompromised patients.

⸻

Chronic Chagas disease

After the acute phase, patients enter a chronic infection.

Many remain in an indeterminate phase, characterized by positive serology without obvious clinical disease.

However, a proportion of infected individuals eventually develop clinically significant organ involvement, sometimes decades after the initial infection.

The major manifestations involve the:

• Heart
• Esophagus
• Colon

⸻

Chagas cardiomyopathy

Cardiac involvement is the most important chronic manifestation of Chagas disease.

Chronic myocardial inflammation and fibrosis can produce progressive cardiomyopathy.

Patients may develop:

• Palpitations
• Presyncope
• Syncope
• Exercise intolerance
• Dyspnea
• Heart failure
• Atypical chest discomfort
• Thromboembolic events

⸻

Arrhythmias and conduction disease

Damage to the cardiac conduction system can produce:

• Bundle branch block
• Atrioventricular block
• Ventricular premature beats
• Ventricular tachycardia
• Other ventricular arrhythmias

Sudden cardiac death may occur from malignant ventricular arrhythmias or complete heart block.

⸻

Apical aneurysm

A characteristic cardiac complication is formation of a left ventricular apical aneurysm.

This can promote:

• Mural thrombus formation
• Systemic embolization
• Ischemic stroke

The presence of an apical aneurysm therefore indicates important thromboembolic risk.

⸻

Gastrointestinal Chagas disease

Destruction of neurons within the enteric nervous system can impair gastrointestinal motility.

The major manifestations are:

• Megaesophagus
• Megacolon

⸻

Megaesophagus

Esophageal dysfunction resembles achalasia.

Patients may develop:

• Dysphagia
• Regurgitation
• Weight loss
• Chest discomfort
• Aspiration

Repeated aspiration can produce respiratory complications.

⸻

Megacolon

Colonic involvement produces progressive dilation and impaired motility.

Manifestations include:

• Severe constipation
• Abdominal distention
• Abdominal discomfort
• Fecal impaction

Advanced disease can occasionally lead to volvulus or bowel obstruction.

⸻

Diagnosis of acute Chagas disease

During acute infection, parasitemia is relatively high, making direct demonstration of circulating parasites possible.

Blood can be examined using:

• Wet preparation
• Thick blood smear
• Thin blood smear
• Giemsa staining
• Buffy-coat examination

Motile trypomastigotes may be visualized in peripheral blood.

Molecular methods such as PCR can also be useful, particularly for acute infection, congenital infection, and suspected reactivation.

⸻

Diagnosis of chronic Chagas disease

Parasitemia becomes very low during chronic infection, so direct microscopy is usually insensitive.

Diagnosis therefore relies primarily on serologic detection of IgG antibodies against T. cruzi.

Available techniques include:

• ELISA
• Indirect immunofluorescence
• Other validated serologic assays

Because no single serologic test has perfect sensitivity and specificity, chronic infection is generally confirmed using two different serologic assays based on different antigens or techniques.

⸻

Evaluation for chronic Chagas complications

Once chronic Chagas disease is identified, patients should be evaluated for organ involvement.

Cardiac assessment

Important investigations include:

• Resting ECG
• Echocardiography

Depending on symptoms and initial findings, additional testing may include:

• Ambulatory ECG monitoring
• Exercise testing
• Additional cardiac imaging

Gastrointestinal assessment

Patients with dysphagia or constipation may require:

• Barium swallow
• Contrast studies of the colon
• Esophageal manometry
• Other gastrointestinal investigations according to symptoms

⸻

Pathology of chronic Chagas disease

Chronic Chagas cardiomyopathy may demonstrate:

• Ventricular enlargement
• Ventricular wall thinning
• Apical aneurysm
• Mural thrombi

Microscopically, the myocardium can show:

• Chronic lymphocytic inflammation
• Interstitial fibrosis
• Myocyte degeneration and atrophy

In megaesophagus and megacolon, there is progressive loss of neurons within the myenteric plexus, leading to dilation and muscular abnormalities.

⸻

Treatment of Chagas disease

The two principal antitrypanosomal drugs are:

Benznidazole

and

Nifurtimox

Treatment is most effective when administered early in the course of infection.

⸻

Benznidazole

Benznidazole is generally preferred because it is usually better tolerated than nifurtimox.

The traditional adult regimen is approximately:

5–7 mg/kg/day orally in divided doses for about 60 days.

Exact dosing depends on age, weight, and contemporary treatment recommendations.

⸻

Nifurtimox

Nifurtimox is an alternative antitrypanosomal drug.

Traditional treatment requires multiple daily doses for a prolonged period.

Adverse effects can limit tolerability.

⸻

Who should receive treatment?

Antiparasitic treatment is particularly important for:

• Acute Chagas disease
• Congenital infection
• Reactivation during immunosuppression
• Children with chronic infection
• Many adolescents and younger adults with chronic infection
• Selected patients who are expected to undergo substantial immunosuppression

Treatment decisions in older adults and patients with established cardiomyopathy should be individualized according to disease severity, age, comorbidities, and expected benefit.

Antiparasitic therapy is considerably more effective at achieving parasitologic cure in younger patients and earlier infection.

Established cardiac and gastrointestinal complications require appropriate organ-specific management in addition to consideration of antiparasitic therapy.

⸻

African trypanosomiasis

Human African trypanosomiasis, or sleeping sickness, is fundamentally different from Chagas disease.

The infection is transmitted through the bite of an infected tsetse fly.

Disease progression is divided into two major stages:

Stage I — Hemolymphatic stage

Parasites are present predominantly in:

• Blood
• Lymphatic system

Stage II — Meningoencephalitic stage

Parasites cross the blood-brain barrier and invade the:

• Brain
• Cerebrospinal fluid
• Central nervous system

Determining the stage is essential because treatment depends on whether CNS invasion has occurred.

⸻

West African trypanosomiasis

Trypanosoma brucei gambiense

This form generally follows a slow, chronic course.

Symptoms may develop over months, and neurologic disease may not appear until months or years after infection.

⸻

Stage I — Hemolymphatic disease

A trypanosomal chancre may develop at the site of the tsetse fly bite.

The lesion may be:

• Painful
• Indurated
• Erythematous
• Occasionally ulcerated

Systemic manifestations subsequently develop.

These may include:

• Intermittent fever
• Headache
• Malaise
• Pruritus
• Arthralgia
• Facial edema
• Peripheral edema
• Rash
• Lymphadenopathy

Lymph nodes are typically enlarged but relatively painless.

⸻

Lymphadenopathy

Posterior cervical lymphadenopathy is a classic feature of gambiense sleeping sickness.

Prominent enlargement of the posterior cervical nodes is traditionally called Winterbottom sign.

⸻

Stage II — Meningoencephalitic disease

Once parasites invade the CNS, neurologic and psychiatric abnormalities develop.

Possible manifestations include:

• Severe headache
• Personality changes
• Behavioral abnormalities
• Irritability
• Confusion
• Tremor
• Fasciculations
• Ataxia
• Abnormal movements
• Progressive somnolence

The normal sleep-wake cycle becomes disturbed, producing the characteristic sleeping sickness syndrome.

As disease progresses, patients may develop:

• Profound neurologic impairment
• Stupor
• Coma
• Death

Without appropriate treatment, advanced disease can be fatal.

⸻

East African trypanosomiasis

Trypanosoma brucei rhodesiense

East African disease is generally much more acute and aggressive than gambiense disease.

Symptoms may begin within days to weeks after infection.

Patients may develop:

• Fever
• Severe headache
• Malaise
• Rash
• Lymphadenopathy
• Trypanosomal chancre

CNS invasion tends to occur earlier.

Cardiac involvement may also be prominent.

Untreated disease can progress rapidly and become fatal within months.

⸻

Diagnosis of African trypanosomiasis

Definitive diagnosis requires demonstration of the parasite.

Organisms may be sought in:

• Blood
• Chancre fluid
• Lymph-node aspirate
• Cerebrospinal fluid

Microscopy can include:

• Wet preparations
• Giemsa-stained preparations

Concentration techniques may increase diagnostic sensitivity when parasitemia is low.

⸻

Serologic screening

Serologic methods have been particularly useful for population screening for T. b. gambiense in endemic settings.

Historically, the card agglutination test for trypanosomiasis (CATT) has been widely used for this purpose.

A positive screening test requires appropriate parasitologic confirmation and staging.

⸻

Lumbar puncture and staging

After African trypanosomiasis is confirmed, assessment for CNS involvement is critical because therapy differs between early and late disease.

Cerebrospinal fluid may demonstrate:

• Increased white blood cells
• Elevated protein
• Trypanosomes

Evidence of CNS involvement indicates stage II disease.

⸻

Treatment of African trypanosomiasis

Treatment depends on:

• Trypanosoma subspecies
• Geographic region
• Stage of disease
• CNS involvement
• Availability of medications

Modern treatment recommendations have evolved considerably, so older textbook regimens should not automatically be applied without checking current guidance.

⸻

West African disease —

T. b. gambiense

Historically, early-stage disease was treated with pentamidine.

Pentamidine does not adequately penetrate the CNS and therefore is not suitable as sole therapy for established late-stage neurologic disease.

For CNS disease, older regimens included eflornithine, while combination approaches and newer oral therapy have substantially changed contemporary management.

Fexinidazole is now an important oral treatment option for eligible patients with gambiense human African trypanosomiasis.

The exact regimen depends on disease severity and current recommendations.

⸻

East African disease —

T. b. rhodesiense

Historically, suramin has been used for first-stage disease.

Because suramin can cause significant adverse reactions, treatment requires careful medical supervision.

Historically, CNS disease was treated with melarsoprol.

Melarsoprol is an arsenical drug associated with substantial toxicity, including potentially fatal encephalopathic reactions.

Treatment of African trypanosomiasis should therefore be coordinated with clinicians and public-health authorities experienced in tropical medicine.

⸻

Prevention

Chagas disease

Prevention focuses on reducing contact with triatomine vectors and preventing nonvector transmission.

Important strategies include:

• Improving housing quality
• Eliminating triatomine infestation
• Using insecticides where appropriate
• Avoiding sleeping in heavily infested structures
• Screening donated blood
• Screening appropriate organ donors and recipients
• Preventing contamination of food and beverages
• Screening individuals at risk for congenital transmission

There is currently no routinely available vaccine.

⸻

African trypanosomiasis

Prevention primarily involves avoiding tsetse fly exposure.

Travelers to endemic areas should:

• Wear long-sleeved clothing
• Wear long trousers
• Avoid known areas of heavy tsetse infestation when possible
• Follow local vector-control advice

No routinely available vaccine prevents African trypanosomiasis.

⸻

Follow-up

Chagas disease

Patients with chronic infection require ongoing assessment for:

• Cardiac conduction abnormalities
• Arrhythmias
• Cardiomyopathy
• Heart failure
• Thromboembolic complications
• Dysphagia
• Megaesophagus
• Constipation
• Megacolon

Periodic clinical assessment and ECG monitoring are particularly important.

Individuals with T. cruzi infection should not donate blood.

Screening may also be appropriate for:

• Children born to infected mothers
• Other family members with similar epidemiologic exposure
• Individuals who lived in endemic regions with substantial vector exposure

⸻

Prognosis

Chagas disease

Many infected individuals remain asymptomatic for life.

However, a substantial minority eventually develop chronic cardiac or gastrointestinal disease.

Chronic Chagas cardiomyopathy can cause:

• Progressive heart failure
• Ventricular arrhythmias
• Complete heart block
• Systemic embolization
• Stroke
• Sudden cardiac death

Cardiac involvement is the major determinant of long-term mortality.

⸻

African trypanosomiasis

Prognosis is excellent when infection is recognized and appropriately treated before advanced neurologic damage occurs.

Untreated disease can progress to severe CNS dysfunction, coma, and death.

The rhodesiense form generally progresses more rapidly than the gambiense form.

⸻

Complications

Chagas disease

Major complications include:

• Dilated cardiomyopathy
• Chronic heart failure
• Ventricular arrhythmias
• Conduction abnormalities
• Sudden cardiac death
• Apical ventricular aneurysm
• Mural thrombus
• Systemic embolization
• Stroke
• Megaesophagus
• Aspiration
• Megacolon
• Severe constipation
• Intestinal obstruction or volvulus

⸻

African trypanosomiasis

Major complications include:

• Meningoencephalitis
• Sleep-wake disturbances
• Neuropsychiatric abnormalities
• Seizures
• Progressive neurologic deterioration
• Coma
• Cardiac involvement
• Death

⸻

High-yield clinical approach

Latin America + kissing bug exposure + unilateral periorbital swelling

→ Think acute Chagas disease with Romaña sign

Chronic T. cruzi infection + palpitations/syncope

→ Think Chagas cardiomyopathy and conduction disease

Chagas disease + ventricular apical aneurysm

→ Increased risk of mural thrombus and embolic stroke

Chagas disease + progressive dysphagia

→ Think megaesophagus

Chagas disease + severe chronic constipation and abdominal distention

→ Think megacolon

Sub-Saharan Africa + tsetse fly exposure + fever and lymphadenopathy

→ Think African trypanosomiasis

Posterior cervical lymphadenopathy

→ Winterbottom sign

African trypanosomiasis + behavioral changes + abnormal sleep pattern

→ Think CNS invasion / stage II sleeping sickness

Slow disease over months to years

→ T. b. gambiense

Rapid, aggressive illness over weeks to months

→ T. b. rhodesiense

⸻

Exam essentials

American trypanosomiasis:

→ Chagas disease

Cause of Chagas disease:

→ Trypanosoma cruzi

Vector:

→ Triatomine/reduviid “kissing” bug

Important transmission mechanism:

→ Parasites in bug feces enter damaged skin or mucosa

Classic acute Chagas finding:

→ Romaña sign

Romaña sign:

→ Unilateral periorbital edema after conjunctival inoculation

Local inoculation lesion:

→ Chagoma

Diagnosis of acute Chagas disease:

→ Demonstration of circulating parasites or molecular detection

Diagnosis of chronic Chagas disease:

→ Serology, generally confirmed with two different assays

Major chronic Chagas complication:

→ Cardiomyopathy

Classic gastrointestinal complications:

→ Megaesophagus and megacolon

Important cardiac structural abnormality:

→ Apical aneurysm

Major causes of death in chronic cardiac Chagas disease:

→ Ventricular arrhythmia, conduction block, heart failure, or thromboembolism

Main Chagas drugs:

→ Benznidazole and nifurtimox

African trypanosomiasis vector:

→ Tsetse fly

West/Central African sleeping sickness:

→ T. brucei gambiense

East/Southern African sleeping sickness:

→ T. brucei rhodesiense

Gambiense disease:

→ Chronic, slowly progressive

Rhodesiense disease:

→ Acute, rapidly progressive

Classic lymph-node finding in African disease:

→ Posterior cervical lymphadenopathy — Winterbottom sign

Stage I African trypanosomiasis:

→ Hemolymphatic disease

Stage II African trypanosomiasis:

→ CNS/meningoencephalitic disease

Characteristic late manifestation:

→ Disruption of the sleep-wake cycle

Critical investigation for staging African trypanosomiasis:

→ Cerebrospinal fluid assessment

Most important treatment principle:

→ Identify the organism and determine whether CNS involvement is present before selecting therapy